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Introduction: Photodynamic therapy (PDT) using 5-aminolevulinic acid-induced protoporphyrin IX 
(ALA-PpIX) constitutes an interesting alternative for cutaneous leishmaniasis treatment.
Objective: To evaluate the production of PpIXbased on the administration of ALA and MAL and the 
effect of ALA-PDTat cellular level on non-infected and infected THP-1 cells using Leishmania (Viannia) 
panamensis or Leishmania (Leishmania) infantum (syn Leishmania chagasi) parasites.
Materials and methods: Protoporphyrin IX (PpIX) production and mitochondrial colocalization were 
evaluated by confocal microscopy. Cell toxicities were evaluated after treatment with the compounds, 
followed by light irradiation (597-752 nm) at 2.5 J/cm2 fluency using a colorimetric MTT assay for 
THP-1 cells and a standard microscopic analysis of parasites. Results were expressed as compound 
concentration activity against 50% of cells or parasites (CC50 or IC50).
Results: ALA or MAL induced an endogenous PpIX with a red fluorescence localized mainly in the 
mitochondria inside human cells. ALA and MAL-PDT induced a similar range of toxicities on THP-1 cells 
(CC50 0.16±0.01mM and 0.33±0.019 mM, respectively) without any apparent inhibition of intracellular 
parasites in the infected cells as compared to untreated controls. Exogenous PpIX-PDT was toxic 
to THP-1 cells (CC50 0.00032±0.00002 mM), L. (L.) infantum (IC50 0.003±0.0001 mM) and L. (V.) 
panamensis (IC50 0.024±0.0001 mM) promastigotes.
Conclusions: Despite the effectiveness of exogenous PpIX on promastigotes and the production of 
PpIX by human infected cells, treatment with ALA or MAL before irradiation was unable to completely 
destroy L. (L.) infantum or L. (V.) panamensis intracellular amastigotes.
Key words: Aminolevulinic acid, photochemotherapy, Leishmania (Viannia) panamensis, Leishmania 
infantum.
doi: http://dx.doi.org/10.7705/biomedica.v34i4.2272 
Acumulación celular y efecto anti-Leishmania de la protoporfirina IX exógena y endógena 
después del tratamiento fotodinámico
Introducción. El tratamiento fotodinámico con ácido 5-aminolevulínico como inductor de la protoporfirina 
IX (ALA-PpIX) constituye una alternativa interesante en el tratamiento de la leishmaniasis cutánea.
Objetivo. Evaluar la producción de protoporfirina IX (PpIX) a partir de la administración de ALA o MAL y 
el efecto de la PDT con ALA a nivel celular en células THP-1 no infectadas e infectadas con Leishmania 
(Viannia) panamensis o Leishmania (Leishmania) infantum (syn. Leishmania chagasi).
Materiales y métodos. La producción de protoporfirina IX y su ‘colocalización’ mitocondrial se 
evaluaron mediante microscopía ‘confocal’. Se evaluó la toxicidad celular después del tratamiento 
con los compuestos y la aplicación de irradiación de luz (597-752 nm) en una fluencia de 2,5 J/cm2 
mediante el empleo de la prueba colorimétrica con metil-tiazol-tetrazolio (MTT) en las células, y de 
métodos microscópicos estándar en los parásitos. Los resultados se expresaron como la concentración 
del compuesto activo en el 50 % de las células o parásitos (CC50 o CI50).
Resultados. El ácido aminolevulínico o el metil-5-aminolevulinato indujeron la protoporfirina IX 
endógena en células humanas, y se observó fluorescencia de color rojo en las mitocondrias. La actividad 
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del ácido aminolevulínico y del metil-5-aminolevulinato utilizados con terapia fotodinámica fue similar 
en las células THP-1 (CC50 0,16±0,01 mM y 0,33±0,019 mM, respectivamente) y, aparentemente, no 
inhibió los parásitos en las células infectadas, en comparación con los controles. El tratamiento exógeno 
con protoporfirina IX y terapia fotodinámica fue tóxico para las células THP-1 (CC50 0,00032 ±0,00002 
mM) y para los promastigotes de L. (L.) infantum (IC50 0,003±0,0001 mM) y L. (V.) panamensis (CI50 
0,024±0,0001 mM). 
Conclusiones. A pesar de la ‘fotoactividad’ del tratamiento con protoporfirina IX en promastigotes y 
de su producción después del tratamiento con ácido aminolevulínico y metil-5-aminolevulinato en las 
células infectadas con Leishmania, no se observó daño en los amastigotes presentes en las células de 
L. (L.) infantum o L. (V.) panamensis. 
Palabras clave: ácido aminolevulínico, fotoquimioterapia, Leishmania (Viannia) panamensis, Leishmania 
infantum. 
doi: http://dx.doi.org/10.7705/biomedica.v34i4.2272 
Leishmaniasis is a heterogeneous parasitic disease 
with a wide spectrum of clinical forms such as 
the cutaneous (CL), the muco-cutaneous (MCL) 
and the visceral (VL) forms. It is a vector borne 
disease caused by several species of the genus 
Leishmania, a digenetic parasite that proliferates as 
motile promastigotes in the gut of sandflies and as 
amastigotes inside vertebrate-host macrophages. 
Leishmaniasis is considered a serious public health 
problem worldwide, as it is endemic in tropical 
and subtropical regions in more than 88 countries. 
Almost 12 million people are currently infected, 
with an annual reported incidence of 1-1.5 million 
cases of CL and 0.5 million cases of VL (1,2). Penta-
valent antimonials (SbV, sodium stibogluconate, 
meglumine antimoniate) followed by amphotericin 
B (AmB), pentamidine isothionate, paromomycin 
and miltefosine constitute the major drug options 
for the disease. These drugs present significant 
drawbacks such as toxicity and side effects, high 
costs, low availability, variable effectiveness and 
high risk of resistance (3,4). The use of topical 
treatments using ointments or cream formulation of 
paromomycin, or physical therapies (electrotherapy, 
thermotherapy, cryotherapy and photodynamic 
therapy or PDT) constitute interesting alternative 
options which must be studied carefully, especially 
in the case of New World leishmaniasis (5,6).
The use of PDT is now widely accepted in derma-
tology against different types of skin conditions 
produced by cancer, aged-related skin degeneration 
or pathogens (7-9). PDT is based on the use 
of a photosensitizer agent which absorbs light 
energy after interaction with visible light and in 
presence of molecular oxygen generates reactive 
oxygen species (ROS) like singlet oxygen and 
the consequent cell damage or cell death (7-9). In 
leishmaniasis, various PS have been used so far 
for PDT, and some of them, such as porphyrins, 
phenothiaziniums analogues, carbaporphyrinketals, 
phthalocyanines (Pc) methylene blue and endog-
enous 5-aminolevulinic acid-induced protoporphyrin 
IX (ALA-PpIX), have demonstrated antileishmanial 
activity in clinical and experimental models (10-16).
ALA-PDT constitutes one of the most successful 
prodrugs used in cancer (17-20). Different topical 
formulations of ALA, methyl-5-aminolevulinate (MAL) 
or other ALA-derivatives have been extensively 
used for treatment of superficial lesions such as 
skin malignancies, actinic keratosis, acne vulgaris, 
psoriasis or skin infections caused by bacteria 
or fungi (17-20). MAL is the active component of 
Metvix®, a topical cream formulation containing the 
hydrochloride salt of methyl-5-aminolevulinate, a 
lipophilic methyl ester of ALA, with photosensitizer 
(PS) prodrug activity (21,22).
ALA is an endogenous metabolite, which is naturally 
synthesized in the mitochondria from glycine 
and succinyl-coenzyme. After several enzymatic 
reactions, it leads to the formation of the heme 
group through the incorporation of Fe++ into PpIX 
by the action of a ferrochelatase enzyme. Since the 
rate of ALA formation is regulated by the amount of 
the concentration of the produced heme (by down-
regulation of transcription and translocation of the 
enzyme ALA synthase), when ALA is administrated 
externally, in the case of ALA-PDT (at 570-670 nm), 
the feedback regulation is bypassed, the capac-
ity of the ferrochelatase enzyme to attach iron 
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decreases and a higher concentration of PpIX is 
accumulated inside the cells becoming a powerful 
photosensitizer for PDT (23).
Recent clinical outcomes of PDT using ALA-PDT in 
patients with CL have been promising, especially on 
those produced by Old World Leishmania species, 
which are refractory to conventional treatments (12-
14). In addition, promising results of ALA-PDT were 
obtained in BALB/c mice infected with L. major (11). 
The animals were treated topically with one dose 
of 20% ALA and PDT. Although there was not a 
complete parasite inhibition, a significant reduction 
of the parasite loads (24.5 folds compared with 
the ALA non-irradiated group), a decrease in 
the percentage of macrophages (from 31.4% to 
2.7%), and necrosis and tissue destruction were 
observed 7 days after ALA-PDT (11). Nonetheless, 
the clinical outcome was not related with in vitro 
results, since no intracellular amastigote elimination 
was observed.
In order to evaluate the effect of ALA-PDT at the 
cell level using New World Leishmania species, the 
production of PpIX based on the administration of 
ALA and MAL by infected and non-infected THP-1 
cells using Leishmania (Viannia) panamensis or 
Leishmania (Leishmania) infantum (syn. Leishmania 
chagasi) parasites was tested. Since no quantita-
tive analysis was carried out to measure the 
levels of ALA or MAL induced-PpIX (endogenous), 




ALA hydrochloride (ALA), methyl 5-aminolevulinate 
hydrochloride (MAL synonym 5-aminolevulinic 
acid methyl ester), PpIX, phorbol 12-mirystate 13- 
acetate (PMA), AmB, 3-(4,5-dimethylthiazolyl)-2,5- 
diphenyltetrazolium bromide (MTT) and haemin 
were purchased from Sigma-Aldrich (St. Louis, USA). 
Dimethyl sulphoxide (DMSO) was obtained from 
Carlo ErbaReagenti (Rodano, Italy). RPMI 1640 
culture medium and fetal calf serum (FCS) were 
obtained from Gibco (Grand Island, NY, USA). 
LysoTracker Green DND-26 was obtained from 
Molecular Probes, Eugene, OR, USA. The mito-
chondrial probe JC-1 (5,5’, 6,6’-tetrachloro-1,1’,3,3’-
tetraethyl benzimidazolyl carbocyanineiodide) 
was kindly donated by Dr. Susana Fiorentino from 
the Grupo de Inmunobiología y Biología Celular, 
Pontificia Universidad Javeriana, Bogotá, Colombia. 
Stock solutions of ALA and MAL were prepared in 
RPMI 1640 medium without fetal calf serum. PpIX 
was dissolved in DMSO. Work solutions were 
prepared with RPMI 1640 medium immediately 
before the experiments. The final concentration of 
the DMSO in work solution was less than 0.5%.
Cells and parasites
Human acute monocytic leukemia THP-1 cells 
(ATCC TIB 202) were maintained in RPMI 1640 
culture medium supplemented with 10% heat 
inactivated (hiFCS) at 37°C in 5% CO2 humidified 
atmosphere. Cells were transformed to the adherent 
phenotype by treatment with PMA (10 ng/mL) for 
72 h. L. chagasi (MHOM/BR/74/PP75) currently 
classified as L. (L.) infantum (24) and L. (V) 
panamensis (MHOM/PA/71/LS94) promastigotes 
were maintained by serial passage in RPMI 1640 
supplemented with 10% hiFCS (v/v) and haemin 
(25 mg/L) at 28°C. For cell infections, transformed 
THP-1 cells in 16-well Lab-Tek™ chamber slides 
(Life Technologies, Paisley, UK) were incubated 
with stationary-phase promastigotes at a ratio of 
1:10 for 24 h at 37°C for L. (L.) infantum or 33°C 
for L. (V.) panamensis. The percentage of infected 
cells was variable in each experiment from 50-70% 
in L. (V.) panamensis and from 60-90% for in L. 
(L.) infantum. The numbers of amastigotes per cell 
were not determined in this study.
Fluorescence microscopy analysis
Infected and non-infected THP-1 cells were incubated 
with three fold dilutions of ALA and MAL (0.16- 5.0 
mM) or exogenous PpIX (0.0062- 0.1 mM). Previous 
experiments using ALA, MAL and PpIX showed that 
lower concentrations did not induce fluorescence 
and higher concentrations than those used in this 
study were toxic in the dark for THP-1 cells. After 
5 h, cells were washed twice with PBS (pH 7.2) 
to remove the excess of compounds and they 
were analyzed microscopically using an Olympus 
FV1000 confocal microscope. The sample was 
excited with a laser at a 488 nm wavelength (λ) 
and the emission was separated with a dichroic 
mirror at λ 580 nm. The images were displayed 
with a red pseudocolor. 
For intracellular localization, cells were incubated 
with 1.6 mM ALA or MAL. After 5 h, cells were 
washed twice and incubated with 10 μg/mL JC-1 
or 100 nMLysoTracker® Green DND-26 for 10 min. 
For the mitochondrial analysis, confocal images 
were taken using a red (PpIX) and green (JC-1) 
pseudocolor. 
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For the lysosomal analysis, cells were examined 
using an epifluorescence microscope (Nikon Eclipse 
E400) with UV-2A filter (Ex=330-380, DM=400, 
BA=420) and B-2A filter (Ex=450-490, DM=500, 
BA=515). 
Images were photographed using a charge-coupled 
device (CCD) color digital camera Nikon Coolpix 
5000. Green (organelle) and red (PS) fluorescence 
images were merged using Adobe PhotoShop 
CS4 software. Colocalization appears as yellow-
orange color. For exogenous PpIX internalization, 
promastigotes and infected and non-infected cells 
were incubated with PpIX (0.0062- 0.1-mM) for 
24 h. The cell internalization was evaluated by 
epifluorescence microscopy as described above.
PDT assays on parasites
Late exponential growth promastigotes were incu-
bated in the dark with ALA and MAL (0.16- 5.0 
mM), exogenous PpIX (0.0003-0.3 mM) and AmB 
(0.03-1.0 μM) at 28°C. After 24 h, the parasites 
were washed once with culture medium after 
centrifugation at 3,000 rpm for 20 min and re-
suspended with normal medium. The cells were 
irradiated at a light fluency of 2.5 J/cm2 using a 
photo reactor equipped with four lamps (50W, 
120V) and filters (Edmund Industrial Optics) to 
select a spectral range from 597 to 752 nm. Control 
cells were maintained without irradiation. Inhibition 
of parasite growth was microscopically determined 
24 h post-irradiation by counting parasite numbers 
in a haemocytometer and calculated by comparison 
to untreated controls. For intracellular amastigotes, 
infected THP-1 cells were incubated with ALA and 
MAL (0.002-5 mM), exogenous PpIX (0.006-1.66 
mM) and AmB (0.03-1.0 μM) for 48 h. Control 
cells were maintained untreated. The cells were 
irradiated as described above. The percentage of 
infected and non-infected cells was microscopically 
counted on methanol fixed and Giemsa-stained 
slides, 72 h post-irradiation. The parasite inhibition 
was determined by comparison to untreated 
controls. The concentration able to inhibit 50 (IC50) 
percent of promastigotes or infected cells was 
calculated by regression analysis (MSxlfit software; 
ID Business Solutions, Guildford, UK). AmB was 
used as antileishmanial control drug active with 
and without light irradiation.
PDT assay on mammalian host cells
Transformed THP-1 cells were incubated with 
three fold dilutions of ALA or MAL (0.01-45.0 mM), 
exogenous PpIX (0.000001-0.015 mM) for 24 h 
at 37°C in 5% CO2 humidified atmosphere. The 
cells were irradiated as described above and cell 
viability was evaluated by a MTT reduction assay 
which measures the mitochondrial dehydrogenase 
activity of surviving cells. A solution of 5 mg/mL 
MTT was added for 4 h and formazan crystals were 
dissolved with DMSO. Optical densities (OD) were 
measured in a microplate reader (Sensident Scan 
Merck) at a wavelength of 580 nm. The percentage 
of THP-1 cell toxicity was calculated: Cytotoxicity 
(%) = 1-(optical density treatment group/optical 
densitycontrol group) x 100. The cytotoxic concen-
tration for 50% (CC50) of cells was calculated by 
sigmoidal regression analysis. THP-1 cells were 
incubated with serial dilution of AmB (3.3-90 μM) 
as stated above and were used as a control for the 
presence of a photoinactive compound.
Statistical analysis
The statistical significance was determined from at 
least two experiments using the two-tailed unpaired 
Student’s t-test. A p value <0.05 was considered as 
statistically significant.
Results 
ALA and MAL treatment induced a red 
fluorescence by infected and non-infected 
THP-1 cells.
An emission of red fluorescence in the cell cyto-
plasm, but not in the nucleus, with a diffuse pattern 
was observed in both Leishmania-infected and 
non-infected THP-1 cells (figure 1a and b). No 
qualitative differences between ALA and MAL red 
fluorescence were observed (data not shown). The 
cellular PpIX production with ALA or MAL (from 
0.16 mM) reached a maximum at 1.6 mM. No red 
fluorescence was observed on untreated cells by L. 
(L.) infantum or L. (V.) panamensis promastigotes. 
However, parasites were able to internalize exog-
enous PpIX as is shown in figure 1c.
ALA and MAL-induced PpIX was localized 
mainly in mitochondria.
A red fluorescence after ALA and MAL treatment 
was overlaid with the green mitochondrial probe 
in Leishmania-infected and non-infected THP-1 
cells (figures 1d-f). A low lysosome colocalization 
was also observed (figure 1g). The mitochondrial 
localization of PpIX after ALA treatment has been 
also demonstrated extensively in cancer cells and 
in J774.2 macrophages infected with Leishmania 
major as described above (11).
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ALA, MAL and exogenous PpIX induced 
photodamage on non-infected THP-1 cells 
after PDT.
Cell photodamage was induced after ALA and MAL-
PDT (CC50 0.16±0.01 mM and CC50 0.33±0.019 
mM, respectively). Some toxicity in non-irradiated 
cells at the maximum concentration evaluated was 
observed (figure 2). Exogenous PpIX-PDT was 
toxic to THP-1 cells (CC50 of 0.00032±0.00002 mM) 
and low toxicities (around 20%) were observed in 
non-irradiated cells (figure 2).
No photo damage was observed after ALA  
and MAL-PDT on promastigotes.
As expected, L. (L.) infantum and L. (V.) panamensis 
promastigotes were not sensitive to ALA and MAL-
PDT. Probably, they were unable to metabolize ALA 
and MAL to produce PpIX. In contrast, exogenous 
PpIX-PDT was phototoxic to L. (L.) infantum (IC50 
0.003±0.0001 mM and IC90 0.004±0.0004 mM) and 
L. (V.) panamensis (IC50 0.024±0 .0001 mM and 
IC90 0.014±0.002 mM) promastigotes (figure 3).
Photodamage in infected host cells was 
observed after ALA and MAL-PDT.
As described above, the incubation of THP-1 
(infected and non-infected) with ALA and MAL 
produces PpIX in observable quantities. PpIX 
produced from ALA and MAL in infected THP-1 
cells did not produce enough phototoxic effect on 
intracellular amastigotes of L. (L.) infantum and L. 
(V.) panamensis to decrease the percentage of 
infection, i.e., there was no parasite elimination. In 
contrast, the numbers of THP-1 cells infected after 
treatment was greater than in untreated controls. 
No differences were observed between ALA 
and MAL-PDT activities (P>0.05).
There were no differences in the toxicities displayed 
by ALA or MAL compounds. 
Antileishmanial activity of amphotericin B 
reference drug
Amphotericin B (AmB) was active against promas-
tigotes and intracellular amastigotes of L. (V.) 
panamensis and L. (L.) infantum without significant 
differences with or without PDT. The antiparasitic 
activities of AmB in PDT untreated (-) versus PDT 
treated (+) parasites are shown in figure 3.
Discussion
Photodynamic therapy (PDT) is based on the 
ability of certain compounds (or photosensitizers) 
to react to light and produce radical oxygen species 
Figure 1. PpIX generation and localization in response to ALA. Microphotographs showed red fluorescence after 1.6 mM ALA for 
5 h in a) non-infected and b) Leishmania-infected THP-1 cells; c) internalization of exogenous PpIX 0.1 mM by L. (L.) infamtum 
promastigotes; (d, e, f) colocalization of endogenous PpIX and JC-1 Green mitochondrial probe on Leishmania-infected THP-1 
cells; d) PpIX red fluorescence; e) JC-1 staining; f) overlay of red and green channels showing colocalization of the two colors; g) 
green and red fluorescence indicating low colocalization of endogenous PpIX with LysoTracker® Green DND-2. These pictures are 
representative of at least 10 fields observed in two independent experiments. 
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which kill the target cell (7-9). ALA and MAL are 
two of the most used endogenous photosensitizers 
and are precursors of PpIX, a high photosensitive 
product (23). As it is known, parasites of the genus 
Leishmania lack several of the enzymes involved 
in the PpIX synthesis and treatment with ALA or 
MAL will not produce a phototoxic effect after PDT 
(24). Accordingly, in this study, no intra-parasite red 
fluorescence or phototoxicity were observed when 
promastigotes were incubated with ALA or MAL 
before irradiation, but in contrast, when incubated with 
exogenous PpIX, red fluorescence and phototoxicity 
were observed. L. (L.) infantum promastigotes were 
more photosensitive to exogenous PpIX than L. (V.) 
panamensis promastigotes, demonstrating once 
again the interspecies intrinsic variation in drug 
sensitivity showed by some antileishmanial drugs, 
such as miltefosine, to which L. donovani (the main 
species involved in Old World leishmaniasis) was 
more sensitive than other Leishmania species. 
Leishmania parasites have been photosensitive 
to different exogenous photosensitizers like Al 
and Zn phthalocyanines, carboporphyrins, and 
benzophenoxazine (10,16,25,26).
The strategy for the use of endogenous ALA or 
MAL against intracellular parasites (it is known that 
amastigotes cannot produce PpIX either) (24), is 
to evaluate the dynamic of PpIX production by the 
infected host cells after ALA treatment because if it 
is produced by the cell, it could be internalized by 
the parasite. Production of PpIX was observed in 
both infected and non-infected differentiated THP-1 
cells. In a previous report, using a Leishmania 
model, Akilov, et al. (11), demonstrated ALA-PpIX 
production in L. major-infected or non-infected J774.2 
cells (immortalized murine BALB/c macrophage 
cells). In those experiments, a low diffuse pattern 
associated with cell membrane and mitochondria 
in non-infected cells and low level diffuse fluores-
cence with bright spots of amastigotes in infected 
ones were observed. Interestingly, intracellular 
amastigotes, but not extracellular ones, were able 
to accumulate time-increased concentration of 
PpIX (11). Production of PpIX based on ALA or MAL 
has been described in several cell lines (27,28). 
Cellular localization is an important issue, since it 
is related with the mechanism of cell death trigger. 
Photosensitizers localized within mitochondria 
are mostly associated with the apoptotic (some 
autophagic) death mechanism involved, i.e., 
caspase (or caspase-independent) activation and 
mitochondrial dysfunction (potential disruption of 
mitochondrial membrane and cytochrome C 
release) giving rise to morphological changes: 
bleeding, chromatin condensation and alteration of 
cell adhesion molecules (29-34). Confocal images 
show overlapping of PpIX red fluorescence and 
MitoTracker Green fluorescence which strongly 
suggest PpIX mitochondrial localization in infected 
and non-infected THP-1 cells. On the other hand, 
low lysosomal localization was observed.
Figure 2. ALA, MAL and PpIX-PDT cell toxicities. PMA-
transformed THP-1 cells were incubated for 24 h with 
increasing concentration of compounds and irradiated at 2.5 
J/cm2. Control cells were kept in the dark (0 J/cm2). After 24 h, 
the percentage of cell toxicity was calculated by comparison 
with untreated controls. The results were expressed as the 
mean ± SD from two experiments (N=8).
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This sub-cellular localization is consistent with 
phototoxicity assays’ results. All compounds 
evaluated (ALA, MAL and PpIX) triggered photo-
toxicity in the non-infected host cell, in agreement 
with previous works (27,28). In this study, the 
amount of PpIX produced by the cells after ALA 
or MAL treatment was not quantified, so it was not 
possible to do a correlation between the activities 
(at CC50 level) achieved with these compounds 
and those achieved with exogenous PpIX on the 
cells, i.e., it cannot be said that using 0.16 mM ALA 
correlates with 0.00032 mM PpIX concentrations 
occurring inside the cells. 
As described above, infected cells also produce 
PpIX based on ALA or MAL, with a low lysosomal 
and high mitochondrial localization. When irradiated, 
PpIX produced from ALA and MAL in infected THP-1 
cells did not produce enough phototoxic effect on 
intracellular amastigotes of L. (L.) infantum and L. 
(V.) panamensis to decrease the percentage of 
infection, i.e., there was no parasite elimination. 
In contrast, the numbers of THP-1 cells infected 
after treatment were greater than on the untreated 
controls. Other studies showed PpIX generation 
from ALA using other tumor macrophage lines and 
determined that the amount of PpIX internalized 
by the intracellular parasites is not sufficient to 
cause photodamage (11). Interestingly, it has been 
reported that ALA derivatives with alkyl chains 
are more easily internalized and more phototoxic 
than ALA itself (30), but no differences between 
ALA and MAL were observed. A poorly enhanced 
internalization (due to just one carbon elongation in 
the lateral chain) or differences in the selectivity of 
the esterase enzymes could be involved in the lack 
of ALA vs. MAL differences shown in this study.
As a conclusion, treatment with ALA or MAL in 
vitro before irradiation with visible light was unable 
to completely destroy L. (L.) infantum or L. (V.) 
panamensis intracellular amastigotes infecting 
THP-1 cells. A fluorescent photosensitizer at the 
mitochondrial level was observed in Leishmania-
infected and non-infected cells. Exogenous PpIX-
PDT was toxic to THP-1 cells and free forms of 
Figure 3. Exogenous PpIX-PDT antiparasitic-activities. Promastigotes of a) L. (V.) panamensis, and b) L. (L.) infantum were 
incubated for 48 h with increasing concentration of the compounds and irradiated at 2.5 J/cm2. Control parasites were kept in the 
dark (0 J/cm2). After 24 h, the percentage of parasite inhibition was calculated by comparison with untreated controls. Amphotericin 
B (AmB) was used as non-phototoxic and reference antileishmanial drug. The results were expressed as the mean ± SD from two 
experiments (N=8).
596
Biomédica 2014;34:589-97Mateus JE, Valdivieso W, Hernández IP, et al.
parasites, but elimination of intracellular amastigotes 
was difficult to define with the methodology used 
in this study. PDT by ALA and MAL-induced 
porphyrin in the host cells could mediate the death 
of intracellular parasites probably due to host cell 
destruction. The response of L. (L.) infantum and 
L. (V.) panamensis to ALA-PDT showed some 
similarities with the response induced by ALA-PDT 
on L. major parasites (16). However, differences in 
the active doses have to be taken into account in 
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